According to the NCI website, Tafasitamab is an Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Check for active clinical trials using this agent. (NCI Thesaurus)
July 31, 2020: FDA approved for use in combination with lenalidomide (BMS/Celgene’s Revlimid) in adult relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
More Information in English: